Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer

European Journal of Cancer Part A

Volumn 32, Issue 10, 1996, Pages 1712-1718

  Otto, F ^b   Schmid, P ^c   Mackensen, A ^c   Wehr, U ^c   Seiz, A ^c   Braun, M ^c   Galanos, C ^a   Mertelsmann, R ^c   Engelhardt, R ^c  

^a MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NONE

Author keywords

Colorectal cancer; Endotoxin phase II; Non small cell lung cancer; T cell; Tolerance

Indexed keywords

ENDOTOXIN; IBUPROFEN; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; MACROPHAGE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0004753309     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00186-4     Document Type: Article

References (30)

1. 1. Coley WB. Contribution to the knowledge of sarcoma. Ann Surg 1891, 14, 199-220.
2. 2. Coley WB. The treatment of malignant tumours by repeated inoculations of erysipelas, with a report of original cases. Am J Med Sc 1893, 105, 487-511.
3. 3. Coley WB. Treatment of inoperable malignant tumors with toxins of erysipelas and the bacillus prodigiosus. Trans Am Surg Assoc 1894, 12, 183-212.
4. 4. Shear MJ, Turner FC, Perrault A. Chemical treatment of tumors. V. Isolation of the hemorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate. J Natl Cancer Inst 1943, 4, 81-97.
5. 5. Sack TH, Seligman AJ. Chemical alteration of polysaccharide from Serratia marcescens. II. Effects of iodopolysaccharide in patients with malignant tumors. J Natl Cancer Inst 1948, 9, 19-34.
6. 6. Vosika GJ, Barr C, Gilbertson D. Phase-I-study of intravenous modified lipid A. Cancer Immunol Immunother 1984, 18, 107-112.
7. 7. Taveira-da-Silva AM, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL. Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 1993, 328, 1457-1460.
8. 8. Berendt MJ, North RJ, Kirstein DP. The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell mediated immunity. J Exp Med 1978, 148, 1550-1559.
9. 9. Carlswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975, 72, 2666-2670.
10. 10. Engelhardt R, Mackensen A, Galanos C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 1991, 51, 2524-2530.
11. 11. Engelhardt R, Mackensen A, Galanos C, Andreesen R. Biological response to intravenously administered endotoxin in patients with advanced cancer. J Biol Response Modif 1990, 9, 480-491.
12. 12. Mackensen A, Galanos C, Engelhardt R. Treatment of cancer patients with endotoxin induces release of endogenous cytokines. Pathobiology 1991, 59, 264-267.
13. 13. Mackensen A, Galanos C, Engelhardt R. Endotoxin tolerance: regulation of cytokine production and cellular changes in response to endotoxin application in cancer patients. Eur Cytokine Netw 1992, 3, 571-579.
14. 14. Andersson J, Melchers F, Galanos C, Lüdertiz O. The mitogenic effect of lipopolysaccharide on bone marrow-derived mouse lymphocytes. Lipid A as the mitogenic part of the molecule. J Exp Med 1973, 137, 843-853.
15. 15. Hoffmann MK, Galanos C, König S, Oettgen HF. B-cell activation by lipopolysaccharide. Distinct pathways for induction of mitosis and antibody production. J Exp Med 1977, 146, 1640-1647.
16. 16. Westphal O, Lüderitz O, Bister F. Über die Extraktion von Bakterien mit Phenol-Wasser. Z. Naturforsch 1952, 7, 148-155.
17. 17. Galanos C, Lüderitz O, Westphal O. Preparation and properties of standardized lipopolysaccharide from Salmonella abortus equi (Novo Pyrexal). Zentralbl Bakterol Parasitenkd Infektionskr Hyg Abt 1979, 243, 226-244.
18. 18. Galanos C, Lüderitz O. Electrodialysis of lipopolysaccharides and their conversion to uniform salt forms. Eur J Biochem 1975, 53, 603-610.
19. 19. Karnofsky DA. Meaningful clinical classification of therapeutic response to anti-cancer drugs. Clin Pharmacol Ther 1961, 2, 709-712.
20. 20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
21. 21. Gamm H, Lindemann A, Mertelsmann R, Herrmann F. Phase I trial of recombinant human tumor necrosis factor alpha in patients with advanced malignancies. Eur J Cancer 1991, 27, 856-863.
22. 22. De Vita VT Jr, Hellman S, Rosenberg SA. Immunotherapy by active specific immunization: clinical applications. In Biologic Therapy of Cancer 1991, 670-682.
23. 23. Parr I, Wheeler E, Alexander P. Similarities of the antitumor actions of endotoxin, lipid A and double-stranded RNA. Br J Cancer 1973, 27, 370-389.
24. 24. Schleimer RP, Rutledge BK. Cultured human vascular endothelial cells acquire adhesiveness for neutrophils after stimulation with interleukin 1, endotoxin and tumor-promoting phorbol diesters. J Immunol 1986, 136, 649-654.
25. 25. Pohlmann TH, Stanness KA, Beatty PG, Ochs HD, Harlan JM. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor alpha increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol 1986, 136, 4548-4553.
26. 26. Yu CL, Haskard DO, Cavender D, Ziff M. Effects of bacterial lipopolysaccharide on the binding of lymphocytes to endothelial cell monolayers. J Immunol 1986, 136, 569-573.
27. 27. Freudenberg MA, Kumazawa Y, Meding S, Langhorne J, Galanos C. Gamma interferon production in endotoxin-responder and -nonresponder mice during infection. Infect Immun 1991, 59, 3484-3491.
28. 28. Mackensen A, Galanos C, Engelhardt R. Modulating activity of interferon-gamma on endotoxin-induced cytokine production in cancer patients. Blood 1991, 78, 3254-3258.
29. 29. Cuturi MC, Murphy M, Costa-Giomi MP, Weinmann R, Perussia B, Trinchieri G. Independent regulating of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med 1987, 165, 1581-1594.
30. 30. Costello R, Imbert J, Olive D. Interleukin-7, a major T-lymphocyte cytokine. Eur Cytokine Netw 1993, 4, 253-262.